The prophylactic effect of verapamil on cardiac symptoms in patients with gastrointestinal cancers

The prophylactic effect of verapamil on cardiac symptoms in patients with gastrointestinal cancers treated with 5-fluorouracil

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251216068357N1

Enrollment

Registered

2025-12-26

Start date

2026-01-04

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Symptoms in Patients with Gastrointestinal Cancers. Personal history of malignant neoplasms of other organs and systems

Interventions

Intervention 1: Intervention group. Intervention 2: Placebo group.

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with gastrointestinal cancers (stomach, pancreas, and colorectal) undergoing treatment with 5-fluorouracil (as part of the FLOT chemotherapy regimen)

Exclusion criteria

Exclusion criteria: Renal failure

Design outcomes

Primary

Measure	Time frame
Ischemic Changes Consistent with ECG. Timepoint: It (the administration) starts 48 hours before chemotherapy and continues until 48 hours after the completion of chemotherapy. Method of measurement: Ischemic Changes Consistent with ECG.	—

Secondary

Measure	Time frame
Age. Timepoint: Start of sampling. Method of measurement: Inquiry.;BMI. Timepoint: Start of sampling. Method of measurement: Kilogram per square meter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactreza zarepour

Kashan University of Medical Sciences

reza_114120@yahoo.com+98 31 5558 9444

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026